Share-based Payment Arrangement, Expense of Prelude Therapeutics Inc from 30 Sep 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Prelude Therapeutics Inc quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2019 to 30 Sep 2025.
  • Prelude Therapeutics Inc Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,423,000, a 59% decline year-over-year.
  • Prelude Therapeutics Inc Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $13,843,000, a 41% decline year-over-year.
  • Prelude Therapeutics Inc annual Share-based Payment Arrangement, Expense for 2024 was $21,345,000, a 17% decline from 2023.
  • Prelude Therapeutics Inc annual Share-based Payment Arrangement, Expense for 2023 was $25,616,000, a 1.9% increase from 2022.
  • Prelude Therapeutics Inc annual Share-based Payment Arrangement, Expense for 2022 was $25,144,000, a 20% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Prelude Therapeutics Inc Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $13,843,000 $2,423,000 -$3,503,000 -59% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $17,346,000 $3,814,000 -$2,284,000 -37% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $19,630,000 $3,832,000 -$1,715,000 -31% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $21,345,000 $3,774,000 -$2,138,000 -36% 01 Oct 2024 31 Dec 2024 10-K 10 Mar 2025 2024 FY
Q3 2024 $23,483,000 $5,926,000 -$789,000 -12% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $24,272,000 $6,098,000 -$635,000 -9.4% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $24,907,000 $5,547,000 -$709,000 -11% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $25,616,000 $5,912,000 +$67,000 +1.1% 01 Oct 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
Q3 2023 $25,549,000 $6,715,000 +$273,000 +4.2% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $25,276,000 $6,733,000 +$705,000 +12% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $24,571,000 $6,256,000 -$573,000 -8.4% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $25,144,000 $5,845,000 +$70,000 +1.2% 01 Oct 2022 31 Dec 2022 10-K 15 Feb 2024 2023 FY
Q3 2022 $25,074,000 $6,442,000 -$591,000 -8.4% 01 Jul 2022 30 Sep 2022 10-Q 01 Nov 2023 2023 Q3
Q2 2022 $25,665,000 $6,028,000 +$1,791,000 +42% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q1
Q1 2022 $23,874,000 $6,829,000 +$2,943,000 +76% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $20,931,000 $5,775,000 +$2,653,000 +85% 01 Oct 2021 31 Dec 2021 10-K 15 Mar 2023 2022 FY
Q3 2021 $18,278,000 $7,033,000 +$5,561,000 +378% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $12,717,000 $4,237,000 +$3,610,000 +576% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $9,107,000 $3,886,000 +$3,524,000 +973% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $5,583,000 $3,122,000 01 Oct 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
Q3 2020 $1,472,000 +$1,175,000 +396% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $627,000 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $362,000 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q3 2019 $297,000 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3

Prelude Therapeutics Inc Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $21,345,000 -$4,271,000 -17% 01 Jan 2024 31 Dec 2024 10-K 10 Mar 2025 2024 FY
2023 $25,616,000 +$472,000 +1.9% 01 Jan 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
2022 $25,144,000 +$4,213,000 +20% 01 Jan 2022 31 Dec 2022 10-K 15 Feb 2024 2023 FY
2021 $20,931,000 +$15,348,000 +275% 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2023 2022 FY
2020 $5,583,000 +$4,737,000 +560% 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
2019 $846,000 01 Jan 2019 31 Dec 2019 10-K 16 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.